{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:22:23Z","timestamp":1790216543091,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106076","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:01:18Z","timestamp":1772085678000},"page":"106076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF\/MEK inhibitors"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4435","authenticated-orcid":false,"given":"E.S.M.","family":"van Aken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-9199","authenticated-orcid":false,"given":"S.M.","family":"O\u2019Cathail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-0963","authenticated-orcid":false,"given":"A.K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-4796","authenticated-orcid":false,"given":"J.","family":"Bussink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-6033","authenticated-orcid":false,"given":"J.G.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Argil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Hiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ka\u017amierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Calles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Konopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7836","authenticated-orcid":false,"given":"G.","family":"Mountzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Putora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Muoio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.M.","family":"Marijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"D.","family":"Martins-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-0905","authenticated-orcid":false,"given":"B.","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.106076_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmoop.2026.106076_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JGO.2015.001545","article-title":"Global access to radiotherapy services: have we made progress during the past decade?","volume":"2","author":"Yap","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib3","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.esmoop.2026.106076_bib5","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.esmoop.2026.106076_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.22555","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib8","first-page":"93","article-title":"Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges","volume":"33","author":"van Aken","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib10","article-title":"Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy","volume":"5","author":"van Aken","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.esmoop.2026.106076_bib11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib13","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib16","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/cancers13194780","article-title":"Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis","volume":"13","author":"Kroeze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106076_bib17","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/JTO.0b013e318257fc1d","article-title":"Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib","volume":"7","author":"Pop","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib19","article-title":"Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma","volume":"27","author":"Amirault","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.esmoop.2026.106076_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/COC.0000000000000501","article-title":"Concurrent radiation and immunotherapy: survey of practice patterns in the United States","volume":"42","author":"Amin","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib21","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1038\/s41598-021-86863-2","article-title":"Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade","volume":"11","author":"Kraus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2026.106076_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"van Aken","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.esmoop.2026.106076_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases. Infectious Diseases Society of America","volume":"18","author":"Gross","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.esmoop.2026.106076_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.esmoop.2026.106076_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.techfore.2020.120484","article-title":"Consensus in the delphi method: what makes a decision change?","volume":"163","author":"Barrios","year":"2021","journal-title":"Technol Forecast Soc Change"},{"key":"10.1016\/j.esmoop.2026.106076_bib27","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2026.106076_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors-impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a molecular target in cancer","volume":"108","author":"Brand","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2005.06.022","article-title":"Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity","volume":"76","author":"Dittmann","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14728222.2015.1012157","article-title":"Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma","volume":"19","author":"Horn","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.esmoop.2026.106076_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2015.02.018","article-title":"Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest","volume":"115","author":"Kriegs","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib35","doi-asserted-by":"crossref","first-page":"45122","DOI":"10.18632\/oncotarget.9161","article-title":"Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests","volume":"7","author":"Kriegs","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.106076_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0271678X19843776","article-title":"A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib - a drug intended for treatment of brain metastases in non-small cell lung cancer","volume":"40","author":"Varrone","year":"2020","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.esmoop.2026.106076_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-018-0566-1","article-title":"Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and\/or leptomeningeal disease","volume":"13","author":"Hochmair","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib39","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib40","article-title":"A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.esmoop.2026.106076_bib41","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: a systematic review and meta-analysis of single-arm trials","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.esmoop.2026.106076_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/ijc.IJC_446_17","article-title":"Cetuximab in combination with chemoradiotherapy for nasopharyngeal carcinoma: a meta-analysis","volume":"55","author":"Wang","year":"2018","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib43","first-page":"1397","article-title":"Cetuximab or nimotuzumab versus cisplatin concurrent with radiotherapy for local-regionally advanced nasopharyngeal carcinoma: a meta-analysis","volume":"19","author":"Liang","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.esmoop.2026.106076_bib44","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3389\/fphar.2020.00706","article-title":"The addition of EGFR inhibitors in neoadjuvant therapy for KRAS-wild type locally advanced rectal cancer patients: a systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2026.106076_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5807346","article-title":"Combining whole-brain radiotherapy with gefitinib\/erlotinib for brain metastases from non-small-cell lung cancer: a meta-analysis","volume":"2016","author":"Zheng","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.esmoop.2026.106076_bib47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.tranon.2018.07.003","article-title":"Efficacy and safety of radiotherapy plus EGFR-TKIs in NSCLC patients with brain metastases: a meta-analysis of published data","volume":"11","author":"Wang","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/cam4.673","article-title":"Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis","volume":"5","author":"Jiang","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib49","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","article-title":"A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320","volume":"85","author":"Sperduto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11060-019-03140-z","article-title":"Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study","volume":"143","author":"Fleischhack","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib51","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"RTOG 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejca.2011.10.016","volume":"48","author":"Pesce","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","article-title":"Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma","volume":"27","author":"Prados","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib54","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.7150\/jca.30123","article-title":"Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial","volume":"10","author":"Du","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26621","article-title":"A pediatric trial of radiation\/cetuximab followed by irinotecan\/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: a Pediatric Oncology Experimental Therapeutics Investigators\u2019 Consortium study","volume":"64","author":"Macy","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju151","article-title":"Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2026.106076_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2016.04.003","article-title":"Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study","volume":"96","author":"Zhou","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11060-019-03282-0","article-title":"The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI)","volume":"145","author":"Yomo","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib59","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.21873\/invivo.11999","article-title":"High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: real world data","volume":"34","author":"Santarpia","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.esmoop.2026.106076_bib60","article-title":"Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective analysis","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.esmoop.2026.106076_bib61","first-page":"1812","article-title":"A pilot study of conformal radiotherapy combined with erlotinib-based multimodality therapy in newly diagnosed metastatic non-small-cell lung cancer","volume":"19","author":"Li","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.esmoop.2026.106076_bib62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12094-017-1723-1","article-title":"Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment","volume":"20","author":"Wang","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib64","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","article-title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial","volume":"28","author":"Ghi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib65","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","article-title":"A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.07.008","article-title":"Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study","volume":"100","author":"Gregoire","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib67","first-page":"192","article-title":"Gefitinib with concurrent chemoradiation in locally advanced head neck cancer","volume":"17","author":"Saini","year":"2018","journal-title":"Gac Mex Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106076_bib68","first-page":"E1770","article-title":"Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma","volume":"38","author":"Yao","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2026.106076_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2019.04.034","article-title":"A phase 1 study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate- and high-risk patients with resected squamous cell carcinoma of the head and neck","volume":"105","author":"Margalit","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib70","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2017.21","article-title":"Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy +\/- cetuximab in oesophageal cancer","volume":"116","author":"Crosby","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib75","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdy105","article-title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75\/08)","volume":"29","author":"Ruhstaller","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib76","first-page":"18","article-title":"Erlotinib vs etoposide\/cisplatin with radiotherapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small-cell lung cancer: a multicenter, randomized, open-label, phase 2 trial","volume":"18","author":"Xing","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13014-019-1239-7","article-title":"Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Liu","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2010.04.010","article-title":"A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results","volume":"71","author":"Choi","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib79","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41416-020-01054-6","article-title":"Chemoradiotherapy with extended nodal irradiation and\/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial","volume":"123","author":"Xie","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2018.01.085","article-title":"Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer","volume":"93","author":"Wu","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cllc.2015.09.008","article-title":"A phase II trial of erlotinib and concurrent palliative thoracic radiation for patients with non-small-cell lung cancer","volume":"17","author":"Swaminath","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2015.02.005","article-title":"Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer","volume":"92","author":"Komaki","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2020.02.002","article-title":"ATOM: a phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI","volume":"142","author":"Chan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12094-013-1035-z","article-title":"Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?","volume":"15","author":"Marquez-Medina","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib85","first-page":"173","article-title":"Efficacy of gefitinib and radiotherapy combination in Indonesian patients with lung adenocarcinoma","volume":"56","author":"Syahruddin","year":"2018","journal-title":"Rom J Intern Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib87","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2026.106076_bib88","author":"Hammel"},{"key":"10.1016\/j.esmoop.2026.106076_bib89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000480295","article-title":"An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204)","volume":"94","author":"Berlin","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.esmoop.2026.106076_bib90","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-018-3682-9","article-title":"Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)","volume":"82","author":"Maurel","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2026.106076_bib91","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.ijrobp.2010.08.050","article-title":"Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer","volume":"82","author":"Robertson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib92","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijrobp.2008.04.065","article-title":"Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer","volume":"73","author":"Bertolini","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib93","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2008.01.046","article-title":"Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL\/0092)","volume":"72","author":"Valentini","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib94","first-page":"23","article-title":"Phase I and II trial on infusional 5-fluorouracil and gefitinib in combination with preoperative radiotherapy in rectal cancer: 10-years median follow-up","volume":"10","author":"Gambacorta","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib95","first-page":"e121","article-title":"Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713","volume":"17","author":"Leichman","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib96","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","article-title":"Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)","volume":"30","author":"Dewdney","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2026.106076_bib99","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2026.106076_bib100","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.esmoop.2026.106076_bib101","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28185","article-title":"The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript","volume":"67","author":"Brunac","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201425","article-title":"Efficacy of ALK inhibitors on NSCLC brain metastases: a systematic review and pooled analysis of 21 studies","volume":"13","author":"Petrelli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.106076_bib104","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s11547-019-00999-w","article-title":"Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group","volume":"124","author":"Borghetti","year":"2019","journal-title":"Radiol Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib106","first-page":"159","article-title":"Radiotherapy and tyrosine kinase inhibitors in stage IV non-small cell lung cancer: real-life experience","volume":"32","author":"Borghetti","year":"2018","journal-title":"In Vivo"},{"key":"10.1016\/j.esmoop.2026.106076_bib107","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.prro.2017.01.001","article-title":"The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases","volume":"7","author":"Miller","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21873\/invivo.11767","article-title":"Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma","volume":"34","author":"Nakashima","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.esmoop.2026.106076_bib109","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.wneu.2016.08.046","article-title":"Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer","volume":"95","author":"Choi","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1016\/j.esmoop.2026.106076_bib111","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jocn.2015.05.068","article-title":"Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy","volume":"26","author":"Dudnik","year":"2016","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.esmoop.2026.106076_bib112","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CAD.0000000000000699","article-title":"Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis","volume":"30","author":"Onesti","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.esmoop.2026.106076_bib113","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/lmt.14.28","article-title":"Concurrent crizotinib and whole-brain radiation for brain metastases in ALK-positive lung adenocarcinoma","volume":"3","author":"Pinto","year":"2014","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.esmoop.2026.106076_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.454","article-title":"Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase-positive lung cancer","volume":"7","author":"Tanigawa","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106076_bib115","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/j.cllc.2020.04.012","article-title":"Intracranial response of ALK non-small-cell lung cancer to second-line dose-escalated brigatinib after alectinib discontinuation due to drug-induced hepatitis and relapse after whole brain radiotherapy followed by stereotactic radiosurgery","volume":"22","author":"Urbanska","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib116","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2015.03.022","article-title":"Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management","volume":"88","author":"Ou","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.03.008","article-title":"Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation","volume":"96","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib118","first-page":"13","article-title":"Symptomatic CNS radiation necrosis requiring neurosurgical resection during treatment with lorlatinib in ALK-rearranged NSCLC: a report of two cases","volume":"11","author":"Zhu","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.esmoop.2026.106076_bib119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-017-1135-8","article-title":"Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib","volume":"193","author":"Zimmermann","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.esmoop.2026.106076_bib120","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.106076_bib121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib122","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.106076_bib123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.106076_bib124","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","article-title":"BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib125","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib126","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.106076_bib127","article-title":"Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?","volume":"2","author":"Alterio","year":"2016","journal-title":"BJR Case Rep"},{"key":"10.1016\/j.esmoop.2026.106076_bib128","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","article-title":"Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma","volume":"31","author":"Anker","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib129","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","article-title":"Vemurafenib and radiosensitization","volume":"149","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.esmoop.2026.106076_bib130","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.prro.2012.11.012","article-title":"Radiation-induced dermatitis with vemurafenib therapy","volume":"3","author":"Churilla","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000367708","article-title":"Localized epidermal cysts as a radiation recall phenomenon in a melanoma patient treated with radiotherapy and the BRAF inhibitor vemurafenib","volume":"6","author":"Houriet","year":"2014","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.esmoop.2026.106076_bib132","first-page":"E4","article-title":"Enhanced radiation dermatitis associated with concurrent palliative radiation and vemurafenib therapy","volume":"98","author":"Kuo","year":"2016","journal-title":"Cutis"},{"key":"10.1016\/j.esmoop.2026.106076_bib133","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00066-014-0707-0","article-title":"Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia","volume":"190","author":"Lang","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.esmoop.2026.106076_bib134","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00066-014-0698-x","article-title":"Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy","volume":"190","author":"Merten","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.esmoop.2026.106076_bib135","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1684\/ejd.2013.2193","article-title":"Severe radiotherapy-induced extracutaneous toxicity under vemurafenib","volume":"23","author":"Peuvrel","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.esmoop.2026.106076_bib136","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO.2013.49.0565","article-title":"Acute radiation skin toxicity associated With BRAF inhibitors","volume":"34","author":"Pulvirenti","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib137","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1684\/ejd.2013.2108","article-title":"Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?","volume":"23","author":"Reigneau","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.esmoop.2026.106076_bib138","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2013.50.8473","article-title":"Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity","volume":"31","author":"Rompoti","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib139","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.jaad.2013.10.046","article-title":"Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma","volume":"70","author":"Saco","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.esmoop.2026.106076_bib140","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","article-title":"Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy","volume":"31","author":"Satzger","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","article-title":"Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports","volume":"190","author":"Schulze","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.esmoop.2026.106076_bib142","first-page":"703","article-title":"Radiosensitization by BRAF inhibitors","volume":"15","author":"Strobel","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.esmoop.2026.106076_bib143","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s13691-016-0260-z","article-title":"Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy","volume":"5","author":"Ueki","year":"2016","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.esmoop.2026.106076_bib144","doi-asserted-by":"crossref","first-page":"522","DOI":"10.12998\/wjcc.v8.i3.522","article-title":"Radiation recall dermatitis with dabrafenib and trametinib: a case report","volume":"8","author":"Yilmaz","year":"2020","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.esmoop.2026.106076_bib145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/CMR.0000000000000682","article-title":"Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis","volume":"30","author":"Ziegler","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib146","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.2017.489","article-title":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients","volume":"118","author":"Hecht","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib147","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib148","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.02.009","article-title":"Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort","volume":"112","author":"Tetu","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib149","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CMR.0000000000000542","article-title":"Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma","volume":"29","author":"Stera","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib151","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CMR.0000000000000250","article-title":"Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib152","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.rpor.2015.07.005","article-title":"Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: a case report","volume":"21","author":"Stefan","year":"2016","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.esmoop.2026.106076_bib153","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2019.04.029","article-title":"Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial","volume":"117","author":"Marti","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106076_bib154","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1158\/1078-0432.CCR-19-4193","article-title":"Phase I trial of trametinib with neoadjuvant chemoradiation in patients with locally advanced rectal cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib155","series-title":"Highlights of prescribing information: Koselugo (selumetinib)","year":"2020"},{"key":"10.1016\/j.esmoop.2026.106076_bib156","series-title":"Highlights of prescribing information: Mekinist (trametinib)","year":"2020"},{"key":"10.1016\/j.esmoop.2026.106076_bib157","first-page":"43","article-title":"Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control","volume":"3","author":"Ghia","year":"2014","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.esmoop.2026.106076_bib158","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib159","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3171\/2017.1.JNS162797","article-title":"Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome","volume":"129","author":"Kotecha","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.esmoop.2026.106076_bib160","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1002\/cam4.3021","article-title":"Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-a retrospective cohort study","volume":"9","author":"Gatterbauer","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2026.106076_bib161","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib162","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3171\/2016.2.JNS1633","article-title":"BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases","volume":"126","author":"Xu","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.esmoop.2026.106076_bib163","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3171\/2014.9.JNS141425","article-title":"Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment","volume":"123","author":"Ly","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.esmoop.2026.106076_bib164","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib165","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-019-03806-5","article-title":"Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report: radiation\/systemic drug combo in metastatic melanoma","volume":"83","author":"Couty","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2026.106076_bib166","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000044","article-title":"Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib","volume":"24","author":"Liebner","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib167","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/tj.5000408","article-title":"Exclusion criteria vs reality: dual BRAF\/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3","volume":"102","author":"Marquez-Rodas","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.esmoop.2026.106076_bib168","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.prro.2015.10.008","article-title":"Integrating radiation therapy with emerging systemic therapies: lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis","volume":"6","author":"Flaum","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.106076_bib169","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-18-2466","article-title":"Clinical Development of novel drug-radiotherapy combinations","volume":"25","author":"Ahmad","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106076_bib170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:12:01Z","timestamp":1777623121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000189"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106076","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF\/MEK inhibitors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106076"}}